Zenas BioPharma CEO & Chairman Discloses 5.16% Stake, Recent $2.4M Share Purchases
ZBIO has more than doubled off its 52-week low of $5.83.
Summary
Zenas BioPharma's CEO and Chairman, Leon O. Moulder, Jr., has disclosed a 5.16% beneficial ownership stake in the company, including recent purchases totaling approximately $2.4 million.
Key Events · Ownership and Investor Activity · ZBIO
-
CEO & Chairman Discloses 5.16% Stake
Leon O. Moulder, Jr., the company's CEO and Chairman, along with affiliated entities, reported beneficial ownership of 2,806,792 shares, representing 5.16% of the outstanding common stock.
-
Recent Open-Market Purchases
Mr. Moulder purchased 100,000 shares in open-market transactions between January 7-9, 2026, at prices ranging from $15.82 to $16.87, totaling approximately $1.64 million.
-
Private Placement Participation
In October 2025, a trust controlled by Mr. Moulder acquired 36,928 shares at $20.85 per share in a private placement, valued at approximately $770,000.
Analysis · ZBIO · Life Sciences
This Schedule 13D filing reveals that Leon O. Moulder, Jr., the Chief Executive Officer and Chairman of Zenas BioPharma, along with entities he controls, beneficially owns 5.16% of the company's common stock. The disclosure highlights significant recent purchases, including approximately $770,000 through a trust in an October 2025 private placement at $20.85 per share, and an additional $1.64 million in open-market transactions in early January 2026 at prices ranging from $15.82 to $16.87. These substantial investments by a key executive signal strong confidence in the company's future prospects, especially given the current stock price of $22.50.
At the time of this filing, ZBIO was trading at $22.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.83 to $44.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.